Bettering rug efficacy towards prostate most cancers and associated bone growths

Improving rug efficacy against prostate cancer and related bone growths

Photo credit: CC0 Public Domain

University of Minnesota researcher Hongbo Pang, published in Advanced Functional Materials, conducted an inter-agency study to improve the effectiveness of nucleotide-based drugs against prostate cancer and bone metastases.

In this study, Pang and his research team investigated whether liposomes, when integrated into the iRGD peptide, help concentrate antisense oligonucleotides (ASOs) in primary prostate tumors and their bone metastases. Liposomes are used as a drug delivery system, and ASOs are a type of nucleotide drug.

More importantly, they were looking to see if this system helps more drugs across the vessel wall and deep into the tumor tissue. This is critical because, while nucleotide drugs offer unique advantages in treating tumors and other diseases, they often suffer from poor efficiency in traversing blood vessels and entering tumor tissue where their targets are. This problem severely limits their clinical applicability and effectiveness.

"Our system shows a good ability to deliver more ASOs to both primary tumor tissue and bone metastases – this is the primary site for prostate cancer metastasis," said Pang, assistant professor at the College of Pharmacy and a member of the Masonic Cancer Center. "This further leads to a significant improvement in ASO efficacy to inhibit the growth of primary tumor and bone metastases. We expect this system to become a universal delivery system to improve the clinical efficacy of ASOs and other nucleotide drugs. "

The study found that:

  • iRGD liposomes may increase tumor accumulation and vascular / tissue penetration by ASOs against the disease-causing gene of prostate cancer;
  • The ability of ASOs to inhibit the growth of both primary tumors and bone metastases was significantly enhanced by iRGD liposomes.
  • and a long-term tumor inhibition study was also conducted which showed that iRGD liposomes significantly prolong AR-ASO suppression of primary tumor growth.

Pang and his team say iRGD liposomes have proven to be a desirable delivery system for ASOs and hold promise to improve the clinical efficacy of nucleotide drugs in cancer therapies.

The therapy creeps into the hard layer of the pancreatic cancer tumor and destroys it from the inside out

More information:
Jibin Guan et al., IRGD Liposomes Improve Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs for Primary Prostate Cancer and Bone Metastases, Advanced Functional Materials (2021). DOI: 10.1002 / adfm.202100478

Provided by
University of Minnesota

Improving Carpet Effectiveness Against Prostate Cancer and Associated Bone Growth (2021, April 20)
accessed on April 20, 2021

This document is subject to copyright. Apart from fair treatment for the purpose of private study or research, no
Part may be reproduced without written permission. The content is provided for informational purposes only.


Please enter your comment!
Please enter your name here